HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FATTY ACID BIOSYSNTHESIS FOR BACTERIAL INFECTIONS
申请人:VITAS PHARMA RESEARCH PRIVATE LIMITED
公开号:US20140249170A1
公开(公告)日:2014-09-04
The present invention relates to novel heterocyclic compounds which specifically inhibit bacterial FabI and can be used for the treatment of Staphylococcal infections.
这项发明涉及一种新型杂环化合物,可以特异性地抑制细菌FabI,并可用于治疗葡萄球菌感染。
US9115149B2
申请人:——
公开号:US9115149B2
公开(公告)日:2015-08-25
[EN] 7-AZAINDOLE INHIBITORS OF CRAC<br/>[FR] INHIBITEURS 7-AZAINDOLE DU CRAC
申请人:HOFFMANN LA ROCHE
公开号:WO2013092467A1
公开(公告)日:2013-06-27
Disclosed are compounds of Formula (I), useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.
7-AZAINDOLE INHIBITORS OF CRAC
申请人:Hoffmann-La Roche Inc.
公开号:US20130158049A1
公开(公告)日:2013-06-20
Disclosed are compounds of Formula (I):
useful for treatment of autoimmune and inflammatory diseases associated with IL-2 inhibition via modulation of calcium release-activated calcium (CRAC) channels. Also disclosed are methods of making and using the compounds for treatment of diseases associated with CRAC channels.